OBJECTIVES: To elicit utility values for health states associated with relapsed/refractory non-Hodgkin lymphoma and compare utilities after adjusting for demographic and societal characteristics in South Korea’s general public.  METHODS: Health state ‘vignettes’ associated with a treatment for R/R non-Hodgkin lymphoma were developed and characterized as: complete response(CR), partial response(PR), stable(SD), progressive disease(PD), and treatment related adverse events(neutropenia, mucositis, thrombocytopenia, anemia; AE). Vignettes were valued by South Koreans using the time trade-off method. The health state vignettes combined information gathered from sources such as published literature, consultations with clinical specialists, and interviews with patients, which were used to develophealth dimensions consistent with the EQ-5D. Utility values were summarized and compared by characteristics of interviewees. The influencing factors of utility values were estimated using mixed Beta regressions. Since the utility values for various health states were measured by a subject, subjects were used as a strata. The glimmix SAS procedure was used to determine factors influencing utility. RESULTS: A total 166 Korean were interviewed. The subjects were aged 46(±10.6) years old with a near even gender split. Mean utilities were CR;0.89(±0.08), PR;0.79(±0.13), SD;0.75(±0.12), PD;0.45(±0.16), AE-neutropenia;0.70(±0.17), AE-mucositis;0.79(±014), AE-thrombocytopenia;0.77(±0.14), and AE-anemia;0.79(±0.13). Utility values for PR and PD were significantly different between males and females (p=0.0135 and p=0.047, respectively). The treatment responses and AE were significant factors in reducing utility values. The ratios of expected utility to disutility (=1-utility) in PR, SD and PD were 0.47, 0.38, and 0.13 times lower than those of CR, respectively. The ratios in AEs(neutropenia, mucositis, thrombocytopenia, and anemia) were 0.45, 0.51, 0.46, and 0.51 times  lower than those of CR, respectively. CONCLUSIONS: This study found that patients’ quality of life was significantly deteriorated by relapsed/refractory non-Hodgkin lymphoma.  It is important to provide an appropriate treatment to improve quality of life.